How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

503 results for

Superficial Thrombophlebitis

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Effects of Functional Electrical Stimulation in Patients Undergoing Coronary Artery Bypass Grafting Surgery

the survey Chronic respiratory diseases Hemodynamic instability Orthopedic and neurological diseases that may preclude the achievement of the cardiopulmonary test and Cardiac Rehabilitation exercises Psychological and/or cognitive impairment that restrict them to respond to questionnaires Changes of skin sensitivity,skin lesion and allergic skin problems Severe lymphedema Uncontrolled diabetes mellitus Acute superficial venous thrombophlebitis Systemic arterial hypertension Contacts and Locations Go

2018 Clinical Trials

122. Study of Peripherally Inserted Venous Catheters in Cystic Fibrosis Patients

with higher scores representing worse outcome. One point is added to a baseline score of 0 for each of the following: indwelling venous material, localized pain, unilateral pitting edema. One point is subtracted for another diagnosis being at least as plausible as venous thrombosis. Secondary Outcome Measures : Development of catheter related local phlebitis or superficial thrombophlebitis [ Time Frame: While the catheter is in place, an average of two weeks ] Phlebitis as defined by a Visual Infusion (...) the IV site; 5- All of the following: Pain, erythema, palpable venous cord and fever >38 degrees centigrade. Thrombophlebitis is defined by phlebitis associated with superficial thrombosis as detected by ultrasound or venogram. Central line associated blood stream infection (CLABSI) [ Time Frame: While the catheter is in place, an average of two weeks ] The study definition for CLABSI follows the Centers for Disease Control guidelines Number of participants with catheter associated deep venous

2018 Clinical Trials

123. Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions

surgery prior to randomization. Subject with history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (DVT; including proximal and distal), pulmonary or arterial embolism, arterial thrombosis or other venous thrombosis within 6 months prior to randomization Note: prior superficial thrombophlebitis is not an exclusion criterion. New-onset seizures or poorly controlled seizures within 12 weeks prior

2018 Clinical Trials

124. What Is Vascular Behçet’s Disease? (PubMed)

are follows; saccular aneurysms without atherosclerosis developed in younger than 50-year-old patients, superior vena cava syndrome or deep vein thrombosis in bilateral legs without apparent causes, and multiple superficial thrombophlebitis, etc. It is very difficult to make a diagnosis of BD in the patients whose onset of the disease is a vascular lesion, because vascular BD combines few ocular lesions. In such case, it is very important to find out not only oral and genital ulceration, but also past

Full Text available with Trip Pro

2018 Annals of vascular diseases

125. Evaluation of the Efficacy and Tolerability of Detralex Treatment in Patients With Chronic Venous Edema (CEAP Class С3) in Real Clinical Practice

of the following concomitant diseases, which can affect the results: Connective tissue disease (including rheumatoid arthritis), arthritis Heart failure Intermittent claudication (peripheral artery disease) Diseases of the bones or joints of the lower extremities Malignancy Treatment with drugs potentially causing leg edema (calcium channel blockers, hormonal drugs, NSAIDs, etc.) History of deep vein thrombosis (within the past year) History of superficial thrombophlebitis (within the past 3 months) Patient

2018 Clinical Trials

126. ChampioNIR® SFA Stent EFS Study

limiting claudication or rest pain (Rutherford-Becker scale 2-4) with a resting ankle-brachial index/toe-brachial index (ABI/TBI) <0.90/0.80. A single superficial femoral artery lesion with >50% stenosis or total occlusion. Stenotic lesion(s) or occluded length within the same vessel (one long or multiple serial lesions) ≥ 40 mm to ≤ 140 mm. Reference vessel diameter (RVD) ≥ 3.0 mm and ≤ 6.0 mm by visual assessment. Target lesion located with the distal point at least 3 cm above the knee joint, defined (...) and tests and are able and willing to provide informed consent. Exclusion Criteria: Thrombophlebitis or deep venous thrombus, within the previous 30 days. Presence of thrombus in the treated vessel as visualized by angiography, prior to crossing the lesion. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved. Poor aortoiliac or common femoral "inflow" (i.e. angiographically defined >50% stenosis of the iliac or common

2018 Clinical Trials

127. Baker's cyst

is based on expert opinion in review articles [ ] and [ ]. Differential diagnosis What else might it be? The differential diagnosis of Baker's cyst includes: Deep vein thrombosis (may mimic ruptured Baker's cyst) — for further information, see the CKS topic on . Superficial thrombophlebitis — for further information, see the CKS topic on . Popliteal artery aneurysm. Popliteal varices. Lipoma. Ganglion cyst. Abscess. Haematoma. Synovial haemangioma. Muscular herniation. Benign or malignant tumours (...) [ ] . Complications of Baker's cyst include: Dissection or rupture. The most common complication is rupture, which may be asymptomatic in up to 80% of people [ ]. Dissection can occur when a cyst expands into the adjacent proximal gastrocnemius muscle belly causing pain, warmth, tenderness, and redness of the calf. Rupture may follow, causing a sudden increase in these symptoms. This is known as pseudo-thrombophlebitis syndrome and can be difficult to distinguish clinically from deep vein thrombosis [ ]. Ruptured

2016 NICE Clinical Knowledge Summaries

128. Evidence-Informed Primary Care Management of Low Back Pain

legend on P.6) Heat or Cold Packs Superficial heat (application of heating pads or heated blankets) is recommended for the short term relief of acute low back pain. Clinical experience supports a role for superficial cold packs and alternating heat and cold as per patient preference. Heat or cold should not be applied directly to the skin, and not for longer than 15 to 20 minutes. Use with care if lack of protective sensation. SR (G1) Analgesia Prescribe medication, if necessary, for pain relief (...) of X-rays is not justified due to the risk of high doses of radiation and lack of specificity. SR (G1, G4, G8) Traction Do not use traction. Traction has been associated with significant adverse events. Passive treatment modalities such as traction should be avoided as mono- therapy and not routinely used because they may increase the risk of illness behaviour and chronicity. The following adverse effects from traction were reported: reduced muscle tone, bone demineralization, and thrombophlebitis

2011 Toward Optimized Practice

129. COMPLI-PICC: Study on Picclines' Complications

in the absence of complications. Infectious complications are described in accordance with IDSA 2009 guidelines and include bloodstream infection, endocarditis, local infection and septic thrombophlebitis. Thrombotic complications are defined as symptomatic, deep, or superficial venous thrombosis, confirmed by Ultrasound and Echo-Doppler or asymptomatic venous thrombosis diagnosed fortuitously. Mechanical complications are defined as impairments related to PICC Line device: occlusion, rupture, accidental

2017 Clinical Trials

130. Utility, Safety, and Effectiveness of the Bard LifeStent 5F Vascular Stent System

by (Responsible Party): C. R. Bard Study Details Study Description Go to Brief Summary: The medical device being examined in this study is the Bard® LifeStent® 5F Vascular Stent System. It is intended for use in patients who suffer from peripheral artery disease (PAD). PAD is generally associated with blocked arteries of the legs. The superficial femoral artery (SFA) and popliteal artery are common locations for this problem to develop. The patient may experience pain or discomfort in the leg that occurs when (...) with percutaneous transluminal angioplasty (PTA) and the Bard® LifeStent® 5F Vascular Stent System. Device: Bard® LifeStent® 5F Vascular Stent System The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm. Outcome Measures Go to Primary Outcome Measures : Freedom from

2017 Clinical Trials

131. Perforator Vein Injection for Symptomatic Venous Disease

significant great or small saphenous reflux Disseminated malignancy or other terminal condition where subject is expected to live less than 6 months. Significant arterial disease (ABI < .8) Buergers disease Acute superficial thrombophlebitis Phlebitis migrans Acute cellulitis Clinical evidence of active local or systemic infection Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using (...) due to venous disease. The investigators believe that venous hypertension is the underlying cause of venous ulceration. Three mechanisms leading to venous hypertension are well-recognized: superficial vein (great, accessory and small saphenous) incompetence; deep vein (common and superficial femoral, popliteal and tibial) reflux or obstruction; perforating vein incompetence. Patients with venous stasis and ulceration may have any or all of these conditions. Currently there are excellent treatments

2017 Clinical Trials

132. Lower Limb Blood Flow Geko vs Foot Pump

electrostimulation (NMES) device A mobile peroneal nerve stimulator Other Name: Geko T-1 Device: Intermittent pneumatic compression (IPC) device A foot pump or foot compression device Other Name: Vadoplex Outcome Measures Go to Primary Outcome Measures : Venous flow at baseline [ Time Frame: "t0" - 30 minutes to include the ultrasound assessment, performed between days 1 and 4 post operatively ] Measured within the superficial femoral vein using ultrasound Venous flow after application of device 1 [ Time Frame (...) : "t1" - 90 minutes to include the ultrasound assessment ] Measured within the superficial femoral vein using ultrasound Venous flow after application of device 2 [ Time Frame: "t2" - 150 minutes to include the ultrasound assessment ] Measured within the superficial femoral vein using ultrasound Secondary Outcome Measures : Patient satisfaction with device 1 [ Time Frame: Immediately after completion of the ultrasound assessment for device 1, at "t1" - 90 minutes ] verbal rating score: 1 extremely

2017 Clinical Trials

133. SecurAcath for securing percutaneous catheters

). Page 7 of 263 3 Clinical e Clinical evidence vidence Summary of clinical evidence 3.1 The key clinical outcomes for SecurAcath given in the decision problem were: rates of catheter migration and dislodgement rates of catheter-related infection, including catheter-related bloodstream infection, local infection or inflammation and thrombophlebitis number of unplanned catheter removals and reinsertions time taken to secure the catheter patient and clinician satisfaction scores pain while in position (...) reported pain at insertion ('if incorrectly placed and the anchor was too superficial') and pain at removal. 3.10 Hill (2014) is a Canadian-based single-centre pilot evaluation of PICCs secured with SecurAcath in 60 patients without a comparator. The author reported no malpositions but accidental dislodgement in 2 agitated patients. The author described dressing changes as being done by 'general unit staff, not IV team staff': SecurAcath gave staff increased confidence, fewer anxieties and increased

2017 National Institute for Health and Clinical Excellence - Medical technologies

134. A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency

demonstrated by a history of peripheral arterial disease (PAD) that would preclude the wearing of compression stockings Absence of a palpable pulse at posterior tibial or dorsalis pedis and an Ankle-Brachial Index (ABI) <0.6 Multi-segmental axial deep venous reflux in at least two contiguous venous segments (e.g., femoral and popliteal) in the ipsilateral extremity Previous surgical or endovenous procedure in the treatment section of the target vein Previous superficial thrombophlebitis of the target (...) Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 50 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: A Prospective, Randomized, Controlled, Multi-Center, Double Blind Study of ClariVein RES for Treatment of Venous Insufficiency Associated With Incompetent Saphenous Veins Due to Superficial Venous Reflux Actual Study Start

2017 Clinical Trials

135. Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

should have vaginal ultrasonography results to confirm an inactive endometrial lining, defined as endometrial thickness less than 4 mm. Exclusion Criteria: Females younger than 30 years of age or older than 75 years of age. Patients with a Serum FSH level of ≤ 40 mIU/mL at Screening. Greater than 5% superficial cells on vaginal cytology. Vaginal pH ≤ 5. Significant history or current evidence of chronic infectious disease, system disorder, organ disorder (including significant liver/kidney impairment (...) 9 months of the study start and all patients will have a physical breast exam performed at Screening. Patients with known, suspected or current history of hormone dependent tumor. Patients with baseline systolic blood pressure of > 150 mmHg and/or diastolic pressure > 90 mmHg. Any patient with undiagnosed vaginal bleeding or significant risk factors for endometrial cancer. Any history of estrogen-dependent neoplasia (e.g., endometrial cancer). History of acute thrombophlebitis or thromboembolic

2017 Clinical Trials

136. JET-RANGER Trial

through bypass graft in aorta-iliac region to get to the target lesion). Has chronic renal insufficiency (eGFR < 30 ml/min or creatinine ≥ 2.5 including dialysis patients). Has planned laser, cryo, TurboHawk or any other treatment except study treatment within 30 days after the index procedure. Has had superficial thrombophlebitis or deep venous thrombus within 30 days prior to index procedure. Has had a stroke within 3 months prior to index procedure. Has had a myocardial infarction within 1 month

2017 Clinical Trials

137. Evaluation of Medical Device

of the need to maintain an intravenous or urinary catheter. Adjusting the prescription in terms of duration or withdrawal of the device in order to limit their complications (lymphangitis, superficial thrombophlebitis, bacteremia related to health care, urinary tract infection). Hypothesis: Limit the length of stay and reduce the cost of hospitalization. Condition or disease Acute Infectious Diseases Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment

2017 Clinical Trials

138. Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy

mIU/mL at Screening. Have ≤ 5% superficial cells on vaginal smear cytology. Have a vaginal pH > 5.0. At least one of the following patient self-assessed moderate to severe symptoms of VVA from the following list that is identified by the patient as being the most bothersome to her: Vaginal Dryness Vaginal and/or Vulvar Irritation/Itching Dysuria Vaginal Pain associated with sexual activity Vaginal Bleeding associated with sexual activity (presence or absence) Provided that patient is currently (...) thrombophlebitis or thromboembolic disorder. Any prescription treatment for vaginal dryness/irritation within 14 days before Screening or any over-the-counter or natural remedies within 7 days before Screening. Any prescription treatment for bacterial or yeast infections within 30 days before Screening. Fasting triglyceride levels > 350 mg/dL. History of radiation therapy or recent (within previous 6 weeks) surgical therapy to the vaginal or cervical areas. Any known or suspected allergies

2017 Clinical Trials

139. Venous Ulcer: Endovenous Radiofrequency Treatment Trial

Collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo Information provided by (Responsible Party): Juliana Puggina, University of Sao Paulo Study Details Study Description Go to Brief Summary: The aim of this study is to analyze the effect of intravenous therapy with radiofrequency for superficial and perforating venous insufficiency versus compression therapy with multilayer banding in patients with active venous ulcer. This is a controlled, randomized prospective clinical trial. People (...) with venous ulcers and primary venous insufficiency in superficial and perforating venous system will be studied. Participants will be divided into two experimental groups: compression therapy alone, and compression therapy associated with superficial and perforating venous system ablation. Clinical aspects, improvement in patients' quality of life and interventions cost-effectiveness will be analyzed. Patients will be followed for 12 months after ulcer healing. Condition or disease Intervention/treatment

2017 Clinical Trials

140. Prophylactic Antibiotics After Cesarean

will be the administration of cephalexin and metronidazole post-operatively for 48 hours. The primary outcome measure will be surgical site infection (including superficial or deep incisional surgical site infection, endometritis, and other related infections, such as septic pelvic thrombophlebitis and abdominal or pelvic abscess) in the post-operative period. In order to most effectively and accurately analyze our primary and secondary research outcomes, the investigators will standardize our surgical operation (...) standard of care Outcome Measures Go to Primary Outcome Measures : Surgical site infection [ Time Frame: 6 weeks postpartum ] Including superficial or deep incisional surgical site infection, endometritis, and other related infections, such as septic pelvic thrombophlebitis and abdominal or pelvic abscess Secondary Outcome Measures : Maternal mortality [ Time Frame: 6 weeks (42 days) postpartum ] Maternal death Febrile morbidity [ Time Frame: 6 weeks (42 days) postpartum ] If the patient develops

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>